Cicor Technologies Ltd.

ladies and gentlemen welcome to the annual media and analyst conference call and live webcast i am alice the course operator i would like to remind you that all participants will be listening only mode and conferences be recorded the presentation will be followed by a q and a session you can register for questions at any time by pressing star and one on your telephone for operator assistance please press star and zero the conference must not be recorded for publication or broadcast At this time, it's my pleasure to hand over to Alexander Hagemann, CEO. Please go ahead, sir.

Thank you very much, Alice. Ladies and gentlemen, thank you for attending to our webcast today. It is for me kind of a special day because the 2022 results are the first where you will see the first results from the growth strategy that we have announced in mid-2021. Therefore, I'm really glad that Peter Neumann, our CFO, and I can present our results 2022 to you. Now, for those of you, there are still a few who don't know SQL that well, Very briefly, what are we doing? We have three core markets, which are the vast majority of what we do, which are medical technology, aerospace defense, and industrial applications. In medical, for example, in hearing aids, SECOR has a very strong position from components to assemblies, with many of the major hearing aid manufacturers worldwide actually one out of three hearing aids uses Sequel technology. Aerospace and defense, the fastest growing application that we have after the acquisition of Axis Electronics, where for example, we provide component for ejection seats for the vast majority of planes. So Sequel technology helps save lives every week. And industrial, one application example here is EUV lithography, where SECOR provides critical technology for the next level of miniaturization, three nanometer chips. So we support our customers to keep Moore's Law alive. Now, when you refer to SECOR and you talk about EMS, Electronic Manufacturing Services, this is actually only a fraction of what we do. We start our collaboration with customers in the development of products from the concept, really from the first beginning of concept development to hardware, software development. These are services that we provide. In industrialization, we do not only talk about prototypes, test concepts, we also talk about validation, which in the case of medical products can easily mean 1,500 pages of documents to get a medical product of our customer to market. Production is also much more than assembly. It's assembly plus, plus, plus. It's assembly plus substrates or PCBs plus precision molding plus printed electronics. So here we differentiate from our competitors through additional and more advanced processes that we use. And after sales here means life cycle management for our customers. For example, managing obsolescence of components. So what we do, we support our customers from cradle to grave of a product. Now, we are having a footprint that brings us always close to our customers, and with the recent acquisitions, we have come much closer to customers in Germany and in the UK. In the meantime, these are 15 sites, 2,500 employees, and we have increased our manufacturing space more than 50% through acquisition and also purchase of factories We need to do that so we can follow the growth that our customers demand from us. The map is therefore more populated than it used to be. Our traditional home market, Switzerland, we now add Germany and the UK as mentioned. In Asia, historically, SECOR is very strong in Southeast Asia compared to China where we only have a small location. This is very helpful with the trends that we see today in supply chain management. Romania is a very strong, our largest European low-cost operation. And I'm extremely glad that through the acquisition of Phoenix Meccano EMS activities, we can now add Tunisia to our footprint. Now let's talk about 2022. This is the third year of unprecedented challenges that started 2020, and no need really to remind anyone of what has happened. Let me only say that there is no playbook that exists. Our colleagues had to take decisions on the spot, had to develop new strategies, how to deal with inflation, supply chain problems, shortages, and other issues. So at the end of the year, we can say we have done well with strategic successes. It is our organic growth coming from a strong pipeline we are reporting about for a few years now, and the acquisitions of Axis and SMT, of Phoenix Meccano EMS activities and AFT, the two latter ones, completed in the first months of 2023. Operational successes were mostly the mastering of the challenges, product shortages, supply chain disruptions, and pricing actions to counter the cost threats from inflation. And the financials that Peter will report about in a few minutes, this is just the result of the successes of the above. Record financials are the result of the strategic and operational achievements of the last year. SECOR has a clear strategic focus. Clear strategic focus on the three core markets, medical, industrial, aerospace, and defense that I've already mentioned. Of course, we have tailwind in aerospace and defense, but not due to the actual developments in Ukraine. It is much more that a few years back, European nations started to invest finally again in their security, and that leads to a long-term growth of that market. In medical and industrial applications, we could also see more than 20% growth, much of that organic growth, so we are very satisfied with how these two markets have developed. Regionally, We have grown our Swiss business by 18% through organic growth. We have grown the US business by more than 20%, again, through organic growth. And in Europe, we have, of course, vastly increased the business as a combination of organic growth and M&A. The only region where we see a very slight decline of 2%, roughly, is in Asia very much coming from us giving up low-margin businesses that we feel don't fit to our strategy and our objectives anymore. Very briefly about our two divisions. The EMS division, of course, now is by far the largest division. It represents more than 85% of our businesses. and is the one where we see a strong acquisitive and organic growth. Almost 40% growth, both as I said, through M&A and also organic. We are very satisfied with that. We are also very satisfied with the margin of 10.7% EBDA margin, the highest ever recorded. You will see that in a few minutes in the multi-year overview that Peter will show. And this very satisfactory EBITDA margin has been the result of pricing actions, especially in the second half, adding of high margin business through acquisition, but also through the new customers we have, and shedding some of the low margin customers. These 10.7% EBITDA margin also position SECOR as one of the most profitable customers EMS providers worldwide. And that is the best jump off point for our growth strategy moving forward into the next years. From an operational perspective, it is important to note that we have more than doubled actually our capacity in Vietnam. We have acquired a factory Last year, we are moving into that factory since January of this year, making very good progress and the move is about half completed. And that gives us the well-needed capacity because we have many new programs that our customers ask us to ramp up in Vietnam this year. Now, the AS division, Advanced Substrate Division, has strengthened its market position and technology leadership through the acquisition of the FinFilm activities from AFT Microwave in Germany, making C-Core the strongest and most technologically advanced provider of FinFilm hybrid substrates in Europe. On the printed circuit board side in PCB, We have seen very good progress in the excellence program, which is there to drive and to push operational excellence forward. Unfortunately, we have suffered from some postponements of orders towards the end of the year, and therefore, overall, we have a slight contraction of top line, about 1%, and the operating margins did not fully reach our objectives. So that leads me to hand over to Peter. Peter will discuss the financial results in detail with you.

Thanks a lot, Alexander. Let me lead you through some of the financials, and let me start with the long-term view. Here you can see we are breaking some records. and I'm very pleased about this, especially if you start with the top line, that we have a combination of a very strong M&A performance plus an organic performance that is very healthy. You can see that in total reported we are plus 31%, and you can see that our excluding acquisitions performance has been 12%. As you can see as well, this is after a negative FX impact. As you all know, the strong Swiss francs against euro, pound, and others has been hurting us as a lot of other companies. The second record is around profitability. We have, again, progressed in terms of our margin by 60 basis points, reaching 10.3. And within this even we have accelerated from the first half to the second half. A comment on something where I got often questions as both the Phoenix Meccano EMS acquisition as well as the AFT Carabout asset deal have been in 2023. There are really no impacts on our 2022 financials. So let's dive deeper into 2022. First of all, The book-to-bill ratio has been very healthy, and across the first half and the second half, we have remained a book-to-bill of 1.15. That gives us a high absolute order book now and a lot of confidence as we go into 2023. Revenue reached a record of 313.2, and this includes a negative FX impact of 4.7 percent, so it's really significant. But as you can see on our profitability, we have been managing some of these challenges well and have progressed on EBITDA 40% and on core EBIT even more than 65%, which shows the strong conversion that we had from top line into bottom line. And all this, clearly, the secret teams have managed to overcomes a lot of by-chain disruptions, cost inflation, and ethics headwinds. Let's talk a bit about our divisions and the divisional performance. EMS is now 86% of the SECO revenue, so the largest portion, and had an excellent year with a strong margin progression. Both Axis and the SMT acquisitions that we consolidated in 2021 and 2022 were in EMS. And as you can see, we are now at a great performance also from a margin standpoint. With 10.7, we are really at the top of our peer group, top class in terms of profitability. The AES division, the positive is we saw some improvement from the first half to the second half. but clearly some pricing actions as well as some of the postponements of orders were giving us very softer results. Looking at the sequential, I mentioned it. You can see here first strong growth across the first half and the second half, but also I think what is even more interesting is that we really accelerated our profitability and our growth on our profit numbers on the EBITDR. We reached 11.1% in the second half versus the 9.5% that we had in the first half. If we dive into the details of our P&L and the income statement you see here, first you can see the EBITDR progression from last year 9.7% to 10.3%. You can see that this comes from, you know, we're losing our capacity much stronger, operational discipline. Material expenses percentage-wise went up, but this is partially driven by broker costs that are diluting this percentage. Here you can also see nicely the impact of why we have the alternative measure core. You can see here the amortization of M&A goodwill intangibles that are $9.2 million. In an IFRS environment, which would be only done via impairment testing to make this really comparable for our wider investor base, we have the core EBIT and the core net profit numbers and take out this impact. And you can see here on the core EBIT numbers that we had a great progression with plus 65.1%. You also can see that financial results, they're – were negative, and this is mainly because we had higher interest costs and also we had some negative ethics impacts there. Some words on net working capital. First, on APAR, you see that they remain in days on hand relatively stable, and you see some improvements on the AP side as we are extending payment terms. On inventory, our focus has really been over the last 12 to 18 months to secure material supply for our customers. This came with incremental inventory, but it helped to avoid major disruption for all our customers. As the supply chain normalized, we will adapt our inventory levels as always to serve our customers best in an efficient way. On CapEx, here you see the absolute CapEx spending in Swiss francs as well. as the depreciation, the ratio of current capex spending to depreciation. You can see that we are within our target corridor, and this includes even a major capacity investment we have taken by the acquisition of a new site in Vietnam that you can see here. Taking out this one, we would have been even at 2.5% of revenue and below at 0.7, 0.8 in terms of capex to depreciation ratio. We ongoingly want to remain at 3% capex or even below as we are kind of focusing on our external growth strategy. The balance sheet increases as we acquired obviously SMT. We issued the MCB and we increased our inventories. Overall, we have a very strong position with a high equity ratio and a low leverage. You can see the 40% equity ratio, 1.4 leverage, so really moderate. So you can see from a financing side, we are now ready for further bold on acquisitions to continue our growth strategy. Cash flow. Looking at our cash flow statement, you can see the choices we made on inventories. to secure materials. This is probably one of the biggest elements here. You see changes in working capital with negative 33 million that have been obviously absorbing a lot of our cash. Secondly, further down, you can see also acquisitions of SMT and the access earned out in the acquisition of subsidiaries. And last but not least, you see the net cash from financing where we had the inflow of the net 59 million from a mandatory convertible bond, and obviously some of the repayments of our syndicated loans. I wanted to draw on the cash flow statement on the first half versus second half performance, because as you can see here, the inventory and the supply chain challenges were probably significant, more important in the first half. And you can see, as we all read, the normalization of some of the supply chains. So you really see a bit of a normalization of this trend. And you can see in the second half, while the most of the changes in working capital, the $28 million in the first half, in the second half, we came more to a stable trend of $5 million cash that we invested there. And also you can see that then our operating cash flow is really strong. And also as we go further, we expect the trends to continue. Last point, it's nice to see the effects of our growth strategy and our 2022 results. But now if you take into account all the acquisitions that we have closed also in the beginning of 2023 – as well as the full impact of SMT, we are already a step ahead. Looking at our results, you see on the left the SQL reported results. If I include pro forma all acquisitions that are closed at this point in time, fully 12-month basis, you can see we obviously have the four months of the beginning of 2022 of SMT. We have Phoenix Meccano, the EMS business, that is considered as the first of January 2023, And we have AFT that closed on the 1st of March. We would be already at 353.3 million revenue and adjusted EBITDIA of 36.2. So we are also on track with our acquisitions delivering positive cash flow and further synergies in 2023. And I think Nysi leads over to Alexander, which provides out to the current year.